Progressive or Recurrent Glioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

 

Glioblastoma (GBM) represents the most common and aggressive primary malignant tumor of the central nervous system in adults. Standard treatment for newly diagnosed GBM typically involves maximal safe surgical resection, followed by a combination of radiotherapy and temozolomide (TMZ) chemotherapy and subsequent six cycles of adjuvant TMZ. Despite this aggressive approach, the median overall survival (OS) for patients with GBM remains poor, ranging from 12 to 18 months, with a 5-year survival rate of less than 7%. Prognostic factors in GBM include patient age and performance status at diagnosis. Younger patients and those with a good performance status—defined by a Karnofsky Performance Score (KPS) greater than 70 or a World Health Organization (WHO) performance status of 0—tend to have better outcomes. Unfortunately, GBM almost invariably recurs after initial treatment, leading to a significantly diminished prognosis. The median progression-free survival (PFS) for recurrent or progressive glioma is only 1.5 to 6 months, while the median OS after recurrence is between 2 and 9 months. Treatment options for recurrent GBM are limited, and effective management remains a significant clinical challenge. Therapeutic strategies for recurrent GBM may include repeat surgery, re-irradiation, and chemotherapy (e.g., bevacizumab, lomustine).

Thelansis’s “Progressive or Recurrent Glioma Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Progressive or Recurrent Glioma treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Progressive or Recurrent Glioma across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Progressive or Recurrent Glioma Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Progressive or Recurrent Glioma – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033